HLA pharmacogenetic markers of drug hypersensitivity from the perspective of the populations of the Greater Middle East

Author:

Masmoudi Hend Chaker123ORCID,Afify Nariman4,Alnaqbi Halima15ORCID,Alhalwachi Zainab1ORCID,Tay Guan K.167ORCID,Alsafar Habiba145ORCID

Affiliation:

1. Center for Biotechnology, Khalifa University of Science & Technology, Abu Dhabi, United Arab Emirates

2. Pharmaceutical Sciences Department, Faculty of Pharmacy of Monastir, Monastir, 5000, Tunisia

3. Department of Histology & Cytogenetics, Institute Pasteur de Tunis, Tunis, 1002, Tunisia

4. College of Medicine & Health Sciences, Khalifa University of Science & Technology, Abu Dhabi, PO Box 127788, United Arab Emirates

5. Department of Biomedical Engineering, Khalifa University of Science & Technology, Abu Dhabi, PO Box 127788, United Arab Emirates

6. Faculty of Health & Medical Sciences, UWA Medical School, University of Western Australia, Perth, 6009, Western Australia

7. School of Medical & Health Sciences, Edith Cowan University, Joondalup, 6027, Western Australia

Abstract

Specific HLA associations with drug hypersensitivity may vary between geographic regions and ethnic groups. There are little to no data related to HLA-drug hypersensitivity on populations who reside in the Greater Middle East (GME), a vast region spanning from Morocco in the west to Pakistan in the east. In this review, the authors intended to summarize the significant HLA alleles associated with hypersensitive drug reactions induced by different drugs, as have been found in different populations, and to summarize the prevalence of these alleles in the specific and diverse populations of the GME. For example, HLA-B*57:01 allele prevalence, associated with abacavir-induced hypersensitivity, ranges from 1% to 3%, and HLA-DPB1*03:01 prevalence, associated with aspirin-induced asthma, ranges from 10% to 14% in the GME population. Studying pharmacogenomic associations in the ethnic groups of the GME may allow the discovery of new associations, confirm ones found with a low evidence rate and enable cost–effectiveness analysis of allele screening before drug use.

Funder

The Center for Biotechnology at the Khalifa University of Science and Technology

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3